» Articles » PMID: 37171645

Overexpression of the LncRNA HOTAIRM1 Promotes Lenvatinib Resistance by Downregulating MiR-34a and Activating Autophagy in Hepatocellular Carcinoma

Overview
Journal Discov Oncol
Publisher Springer
Specialty Oncology
Date 2023 May 12
PMID 37171645
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common malignant cancers in humans and has a high fatality rate. Despite pharmacological advances such as sorafenib and lenvatinib approval, responses are seen only in a limited fraction of HCCs, and the majority of HCC patients do not benefit from this treatment. In recent years, researchers have verified that the long noncoding RNAs (lncRNAs) impact the efficiency of lenvatinib and the prognosis of patients with HCC.

Materials And Methods: This work obtained gene expression profile from an Arraystar lncRNA microarray. Expression of HOTAIRM1, Beclin-1, and p62 in HCC was characterized in clinical HCC tissues of 24 patients with HCC. Overexpression and knockdown experiments were performed in HCC cells to examine the effects of the HOTAIRM1 on lenvatinib sensitivity. The interactions between HOTAIRM1, miR-34a and Beclin-1 were predicted according to GSEA and CNC network. The effects of HOTAIRM1, autophagy and lenvatinib on tumor inhibit were validated in orthotopic tumor-bearing nude mouse model.

Results: Lenvatinib-resistant HCC cell lines were established using the concentration gradient method. Data from an Arraystar lncRNA microarray indicated that HOTAIRM1, a specific lncRNA located in an evolutionarily highly conserved HOX gene cluster, was differentially expressed between lenvatinib-resistant HCC cells and their parental cells. Expression of HOTAIRM1 and Beclin-1 in HCC was characterized in clinical HCC tissues of 24 patients who have different sensitivity to lenvatinib. Knocking down of HOTAIRM1 decreased the autophagy level in lenvatinib-resistant HCC cells and increased their sensitivity to lenvatinib, especially when combined with autophagy inhibitors both in vitro and in vivo. Further study indicated that knocking down HOTAIRM1 in lenvatinib-resistant cell lines increased the level of miR-34a and inhibited the expression of Beclin-1 in Huh7-R and HepG2-R cells. Investigation according to GSEA and CNC network, lncRNA and nearby coding gene and lncRNA-miRNA analyses demonstrated that the resistance of HCC to lenvatinib was affected by the HOTAIRM1-miR-34a-Beclin-1 regulatory axis.

Conclusion: HOTAIRM1 is an independent drug resistance factor which significantly associated with the efficacy of lenvatinib in HCC. HOTAIRM1 may downregulation of miR-34a and upregulation of Beclin-1, leading to activation of autophagy, thereby inducing lenvatinib resistance in HCC.

Citing Articles

The role of miR-16 and miR-34a family in the regulation of cancers: A review.

Sadeghi Z, Malekzadeh M, Sharifi M, Hashemibeni B Heliyon. 2025; 11(4):e42733.

PMID: 40061926 PMC: 11889592. DOI: 10.1016/j.heliyon.2025.e42733.


Lipid Nanoparticle (LNP) -A Vector Suitable for Evolving Therapies for Advanced Hepatocellular Carcinoma (HCC).

Zhang M, Guo R, Yuan Z, Wang H Glob Chall. 2025; 9(1):2400217.

PMID: 39802046 PMC: 11717671. DOI: 10.1002/gch2.202400217.


Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review).

Ye G, Ye M, Jin X Am J Cancer Res. 2024; 14(9):4113-4171.

PMID: 39417171 PMC: 11477829. DOI: 10.62347/UJVP4361.


MicroRNAs in Hepatocellular Carcinoma Pathogenesis: Insights into Mechanisms and Therapeutic Opportunities.

Mahboobnia K, Beveridge D, Yeoh G, Kabir T, Leedman P Int J Mol Sci. 2024; 25(17).

PMID: 39273339 PMC: 11395074. DOI: 10.3390/ijms25179393.


Exploring non-coding RNA mechanisms in hepatocellular carcinoma: implications for therapy and prognosis.

Tian Y, Zhang M, Liu L, Wang Z, Liu B, Huang Y Front Immunol. 2024; 15:1400744.

PMID: 38799446 PMC: 11116607. DOI: 10.3389/fimmu.2024.1400744.


References
1.
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

2.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

3.
Zhang X, Weissman S, Newburger P . Long intergenic non-coding RNA HOTAIRM1 regulates cell cycle progression during myeloid maturation in NB4 human promyelocytic leukemia cells. RNA Biol. 2014; 11(6):777-87. PMC: 4156508. DOI: 10.4161/rna.28828. View

4.
Lin M, Pedrosa E, Shah A, Hrabovsky A, Maqbool S, Zheng D . RNA-Seq of human neurons derived from iPS cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders. PLoS One. 2011; 6(9):e23356. PMC: 3168439. DOI: 10.1371/journal.pone.0023356. View

5.
Li P, Zhang X, Wang H, Wang L, Liu T, Du L . MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2. Mol Cancer Ther. 2017; 16(4):739-751. DOI: 10.1158/1535-7163.MCT-16-0591. View